HomeCompareNHIQ vs PFE

NHIQ vs PFE: Dividend Comparison 2026

NHIQ yields 16666.67% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NHIQ wins by $8601297707047409664.00M in total portfolio value
10 years
NHIQ
NHIQ
● Live price
16666.67%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8601297707047409664.00M
Annual income
$8,500,961,637,704,150,000,000,000.00
Full NHIQ calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — NHIQ vs PFE

📍 NHIQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNHIQPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NHIQ + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NHIQ pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NHIQ
Annual income on $10K today (after 15% tax)
$1,416,666.67/yr
After 10yr DRIP, annual income (after tax)
$7,225,817,392,048,527,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, NHIQ beats the other by $7,225,817,392,048,527,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NHIQ + PFE for your $10,000?

NHIQ: 50%PFE: 50%
100% PFE50/50100% NHIQ
Portfolio after 10yr
$4300648853523704832.00M
Annual income
$4,250,480,818,852,075,000,000,000.00/yr
Blended yield
98.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

NHIQ
No analyst data
Altman Z
-13.3
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NHIQ buys
0
PFE buys
0
No recent congressional trades found for NHIQ or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNHIQPFE
Forward yield16666.67%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$8601297707047409664.00M$49.6K
Annual income after 10y$8,500,961,637,704,150,000,000,000.00$26,258.71
Total dividends collected$8594666089931243520.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NHIQ vs PFE ($10,000, DRIP)

YearNHIQ PortfolioNHIQ Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,677,367$1,666,666.67$9,153$693.39+$1.67MNHIQ
2$263,066,849$261,272,066.46$8,593$849.25+$263.06MNHIQ
3$38,576,943,838$38,295,462,310.00$8,336$1,066.78+$38576.94MNHIQ
4$5,289,656,888,585$5,248,379,558,677.81$8,437$1,384.80+$5289656.88MNHIQ
5$678,235,585,150,030$672,575,652,279,244.40$9,013$1,875.40+$678235585.14MNHIQ
6$81,321,145,183,775,540$80,595,433,107,665,010.00$10,306$2,680.72+$81321145183.77MNHIQ
7$9,118,299,079,523,715,000$9,031,285,454,177,076,000.00$12,820$4,101.38+$9118299079523.70MNHIQ
8$956,159,646,381,740,000,000$946,403,066,366,649,700,000.00$17,673$6,826.70+$956159646381740.00MNHIQ
9$93,772,027,423,605,150,000,000$92,748,936,601,976,690,000,000.00$27,543$12,591.86+$93772027423605152.00MNHIQ
10$8,601,297,707,047,409,000,000,000$8,500,961,637,704,150,000,000,000.00$49,560$26,258.71+$8601297707047409664.00MNHIQ

NHIQ vs PFE: Complete Analysis 2026

NHIQStock

NantHealth, Inc., together with its subsidiaries, operates as a healthcare IT company in the United States, Canada, and the United Kingdom. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. The company also provides NaviNet, a suite of SaaS-based solution enabling payers and providers to streamline communication and consolidate information; NaviNet Open, a payer-provider collaboration platform for communication between health plans and providers; NaviNet AllPayer that provides eligibility, benefit, and claim status information to provider offices for commercial and government plans, and centers for medicare and medicaid services for Medicare beneficiaries through the NaviNet portal; and OpenNMS is an open-source network monitoring solution for enterprise-grade networks. In addition, it offers Quadris, a data solution that includes multi-data analysis, reporting, and professional services. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was incorporated in 2010 and is headquartered in Morrisville, North Carolina. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.

Full NHIQ Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this NHIQ vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NHIQ vs SCHDNHIQ vs JEPINHIQ vs ONHIQ vs KONHIQ vs MAINNHIQ vs JNJNHIQ vs MRKNHIQ vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.